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ABSTRACT
Context: Digoxin is a commonly used inotropic drug that has a narrow therapeutic range and is monitored poorly for its plasma concentration. It is 
commonly used in the management of cardiovascular disorders for its inotropic effects. Increased risk of chronic digoxin toxicity among the patients 
receiving digoxin pharmacotherapy is related to its narrow therapeutic range. Apart from its inotropic properties, it can also produce chronotropic 
and dromotropic effect. Its serum levels vary due to changes in body weight, age, renal function, hepatic impairment, and concomitant drug 
administrations. Patients receiving digoxin should be monitored periodically for potential drug interactions, adverse effects, toxicity, and other drug-
related problems. Symptoms of digoxin-induced cardiotoxicity are difficult to be identified and may become fatal too. Therapeutic drug monitoring 
will play a significant role in reducing such drug therapy problems and will ensure safety and efficacy of the given drug.
Case Report: We report a case of chronic digoxin toxicity in a 22-year-old male with congestive cardiac failure - Class IV and atrial fibrillation with 
ventricular bigeminy.
Results: Patient’s renal parameters were elevated and among electrolytes, sodium level was decreased and potassium level was increased. A reduction 
in the volume of the distribution of digoxin, due to impairment of renal function or congestive cardiac failure, might be one of the reasons for digoxin 
toxicity. Drug therapy problems (DTPs) such as untreated indication, inappropriate drug therapy, potential major drug-drug interactions, and drugs 
prescribed when contraindicated were observed.
Conclusion: Monitoring digoxin drug therapy can bring down the risk of digoxin intoxication.
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INTRODUCTION
Digoxin, a cardiac glycoside, is commonly used in the management 
of cardiovascular disorders such as congestive cardiac failure 
and cardiac arrhythmias for its inotropic effects. Increased risk 
of chronic digoxin toxicity among the patients receiving digoxin 
pharmacotherapy is related to its narrow therapeutic range (0.8–
2 ng/ml) [1]. Apart from its inotropic properties, it can also produce 
chronotropic and dromotropic effect [2]. Symptoms of digoxin-
induced cardiotoxicity are difficult to be identified and may become 
fatal too [3]. In this article, we discuss a case of digoxin intoxication in 
a clinical pharmacist perspective.
CASE REPORT
A 22-year-old man, Mr. X, was admitted to the coronary care unit 
through emergency.
Presenting complaint
Mr. X had been suffering from abdominal pain, reduced urine output, 
loss of appetite (symptoms of digoxin toxicity), loss of weight, and 
constipation for the past 1 week. He was also suffering from excessive 
cough and Class II–IV dyspnea. After admission, on the 6th day, he 
developed visual disturbance and delirium.
Mmedical history
Mr. X’s medical history included acyanotic congenital heart disease, 
congestive cardiac failure-Class IV, hyperacidity, and asthma. He was 
diagnosed with congenital corrected transposition of the great arteries 
at 17 years of age.
Medication history








per minute (irregular). His jugular venous pressure (JVP) elevated up to 
the angle of mandible (An elevated JVP is typically a sign of congestive 




Cardiovascular system(CVS): Upon CVS examination, Heart sound S1 
was normal whereas S2 was irregular with apical impulse hyperdynamic 
over right midaxillary region. Parasternal  heave was positive, grade IV/
VI presystolic murmur over apical area and grade II/VI high pitched 
early diastolic murmur over pulmonary area was observed. A positive 
bilateral air entry and fine crepts was perceived on examining the 
respiratory system. Upon palpation, per abdomen was soft, fluid was 
present (++) and huge hepatomegaly was noticed.
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suggestive of digoxin toxicity.
•	 ECHO	showed	situs	solitus,	dextrocardia,	severe	pulmonary	arterial	
hypertension (PAH), severe left-sided atrioventricular (AV) valve 
regurgitation, mild right-sided AV valve regurgitation, dilated left 
atrial, intra-atrial septum (IAS) bulging toward the right atrium, 
intact IAS/intraventricular septum, and severe biventricular 
dysfunction.

















The patient was symptomatically treated pending his biochemical 
and clinical investigation results. After the patient developed visual 
disturbances and delirium (symptoms of digoxin toxicity), digoxin 
was stopped immediately. Mr. X was managed symptomatically and 
improved very well initially. Transposition of the right arteries with 
intact septum was corrected, and then, the case was discussed in a 
multidisciplinary heart team meeting and was advised orthotropic 
heart transplantation. Meanwhile, Mr. X’s bilirubin levels got elevated 
and	he	deteriorated	once	 again	developing	 acute	 renal	 failure	 (ARF).	
Even	though	he	was	treated	with	inotropes	symptomatically,	no	further	
significant improvement was observed in his condition, and therefore, 
the only treatment option left behind was heart transplantation.
DTP involved
DTPs are usually related to indication, effectiveness, safety, and 
adherence of drug therapy. DTPs observed in this patient are listed as 
follows:
Potential drug interactions:







Seven moderate and two minor potential drug-drug interactions were 
also observed.
Untreated indication: Huge hepatomegaly.
Wrong Dose: Milrinone 0.01 mcg/kg/min was given to Mr. X.
However,	the	recommended	dose	of	milrinone	for	CHF	patients.
•	 Loading	dose:	50	mcg/kg	over	10	min	and	the	maintenance	dose	is	
titrated based on the hemodynamic and clinical response.
•	 Maintenance	dose:	0.375–0.75	mcg/kg/min.
Contraindications
The Table 1 indicates the drugs that are contraindicated and the clinical 
reason for its forbidden use in this patient.
DISCUSSION
Causes of digoxin toxicity
Digoxin is a drug with narrow therapeutic range and its serum levels vary 
due to changes in body weight, age, renal function, hepatic impairment, 
and concomitant drug administrations. An impaired volume of the 
distribution of digoxin, due to reduced renal function (digoxin is excreted 
mainly by the kidneys) or congestive cardiac failure, might be one of the 
reasons for digoxin toxicity [6,7]. In Mr. X’s case, his renal function was 
deteriorating	and	he	developed	ARF	and	congestive	cardiac	failure.
Chadha et al. have reported that digoxin is a drug with narrow 
therapeutic index and can cause life-threatening arrhythmias when the 
plasma	levels	rise	>2	ng/ml.	Renal	insufficiency	interactions	with	other	
drugs that affect digoxin metabolism and electrolyte abnormalities 
(particularly	hypokalemia)	are	the	risk	factors	for	digoxin	toxicity	[8,9].	
Similarly, Mr. X’s renal parameters were elevated and among electrolytes, 
sodium level was decreased and potassium level was increased to 
6.12 mmol/L. Hyperkalemia is a major concern in digoxin toxicity 
[10,11]. Potential drug-drug interactions might have also summed up 
the risk of hyperkalemia in him. Sani has reported that concomitant 
drugs prescribed (such as amiodarone, calcium antagonists, quinine, 
diuretics, and indomethacin) may interfere with the plasma protein 
binding of digoxin [4]. Mr. X was also receiving diuretics that might have 
increased the risk of digoxin toxicity.
Bremner	 et al. have stated that it is significant to monitor plasma 
electrolyte levels and pH frequently in patients with digoxin toxicity. 
Digoxin intoxication may lead to hyperkalemia by generalized cellular 
loss of potassium with subsequent cardiac arrest. Induction of 
hyperkalemia has been proposed as a therapeutic measure in digoxin 
overdosage, as elevated plasma potassium levels antagonize glycoside 
uptake at the sodium-potassium pump site [4,12,13]. In context to that, 
Mr. X’s potassium level was also elevated and hyperkalemia was left 
untreated monitoring potassium levels frequently.
Clinical features of digoxin toxicity
In Mr. X’s case, cardiac effects include complete heart block and non-
cardiac effects are abdominal pain, reduced urine output, loss of 
appetite, visual disturbances, and delirium. This can be supported 
the statement of Sani, “clinical features of digoxin toxicity can be 
categorized into cardiac and non-cardiac effects” [6].
Table 1: Drugs contraindicated in this patient with its reason [4,5]
Drug Reason for contraindication (as per BNF)
Digoxin Intermittent complete heart block, atrial fibrillation, heart failure, and renal impairment
Dobutamine Increases the risk of rapid ventricular response in patients with a history of atrial fibrillation.
Fentanyl Renal	or	hepatic	impairment
Furosemide Hyponatremia, anuria, or renal failure. Hepatic or renal impairment
Pantoprazole Hepatic impairment
Spironolactone Hyperkalemia, hyponatremia, anuria, and renal impairment (avoid if renal parameters rapidly deteriorating)
Tramadol Renal	or	hepatic	impairment
3
Asian J Pharm Clin Res, Vol 11, Special issue 4, 2018, 1-3
 Punniyakotti et al. 
Mr. X was discharged on request despite being in an unstable condition 
(inotropic support). He was given furosemide, losartan, and pantoprazole.
CONCLUSION
Patients receiving digoxin, a drug with narrow therapeutic index should 
be monitored periodically for potential drug interactions, adverse 
effects, toxicity, and other drug-related problems. Therapeutic drug 
monitoring will play a significant role in reducing such DTP and will 
ensure safety and efficacy of the given drug.
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